Intermediate-stage patients HCC who are about to receive their first time TACE treatment PIVKA-II, intermediate stage HCC, TACE
Conditions
Interventions
Intermediate-stage HCC patients who are 18 years of age or older and are suitable for TACE are receiving their first-time TACE treatment.
Diagnostic
Intermediate-stage HCC patients
Sponsors
Khon Kaen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Intermediate-stage HCC patients who are 18 years of age or older and are suitable for TACE are receiving their first-time TACE treatment.
Exclusion criteria
Exclusion criteria: 1.HCC that is not in the intermediate stage. 2.HCC that is not suitable for TACE. 3.Patients who have previously received treatment with liver resection, ablation, percutaneous ethanol injection, systemic treatment, or other forms of HCC treatment. 4.Contraindicate for TACE 5.Patients with a history of liver resection/surgery or liver transplantation 6.Baseline serum PIVKA-II levels < 23.6 ng/mL 7.Patients with vitamin K deficiency or currently taking warfarin 8.Do not consent to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage reduction in serum PIVKA-II levels Compare baseline PIVKA-II levels to those at 2 and 8 weeks after TACE Elecsys test, Protein induced by vitamin K absence or antagonist II (PIVKA-II) | — |
Secondary
| Measure | Time frame |
|---|---|
| Accuracy of percentage reduction in serum PIVKA-II levels Compare baseline PIVKA-II levels to those at 2 and 8 weeks after TACE Elecsys test, Protein induced by vitamin K absence or antagonist II, AUCs | — |
Countries
Thailand
Contacts
Public ContactNapapong Nitiwaranggoon
Faculty of Medicine, Khon Kaen University
Outcome results
None listed